首页
外语
计算机
考研
公务员
职业资格
财经
工程
司法
医学
专升本
自考
实用职业技能
登录
医学
The patient who takes interest in everything and everybody is a formidable adversary for disease.
The patient who takes interest in everything and everybody is a formidable adversary for disease.
admin
2021-11-29
61
问题
The patient who takes interest in everything and everybody is a
formidable
adversary for disease.
选项
A、dreadful
B、principal
C、potential
D、imaginary
答案
A
解析
题干:对每一个人和每一件事物都感兴趣的病人将会成为疾病打不倒的人。formidable可怕的,难克服的;dreadful可怕的,厉害的;principal主要的;potential潜在的;imaginary想象的。根据题意,本题选A。
转载请注明原文地址:https://kaotiyun.com/show/92H3777K
本试题收录于:
医学博士外语题库考研分类
0
医学博士外语
考研
相关试题推荐
Imagineadiseasespreadingacrosstheglobe,killingmostlymiddle-agedpeopleorleavingthemchronicallydisabled.Thenoned
Imagineadiseasespreadingacrosstheglobe,killingmostlymiddle-agedpeopleorleavingthemchronicallydisabled.Thenoned
Cultureshockmightbecalledanoccupationaldiseaseofpeoplewhohavebeensuddenlytransplantedabroad.Likemostailments,
A、Ariseineggprice.B、Ahighincidenceofheartdisease.C、Adropineggsales.D、Theemergenceofanewlifestyle.C录音讲到人们发
Onlynative-borncitizensareeligiblefortheU.S.presidency.
Whydopeoplealwayswanttogetupanddancewhentheyhearmusic?Theusualexplanationisthatthereissomethingembeddedin
A、Regularphysicalactivity.B、Increasedself-confidence.C、Thebettermood.D、Theabilitytoconcentrate.A从“Andchildrenwhoe
Therosemaryplantisanemblemoffidelityandremembrance.
Thisgrowthinthe______ofdiabetesisdue,inpart,toanincreaseinobesity.
Therosemaryplantisanemblemoffidelityandremembrance.
随机试题
小李是北京某政法学院教务处的工作人员,法律系提交了2012级四个法律专业教学班的期末成绩单,为更好地掌握各个教学班学习的整体情况,教务处领导要求她制作成绩分析表,供学院领导掌握宏观情况。请根据考生文件夹下的“Excel素材.xlsx”文档,帮助小李完成20
用添弧的方法找出下图中邮递员的最优投递路线(▲代表邮局).
在Word中,利用______可以很直观地改变段落的缩进方式,也可以调整页的左右边距。
膀胱造影的术前准备,不包括
动物分泌雄激素的主要器官是()
A.五脏六腑病证B.表里经脉病证C.五脏病证D.六腑病证E.急性病证原穴主要治疗
吕某,女,15岁,为某市中学生,是一起抢劫案的目击证人,下列有关公安机关在询问吕某过程中应当遵守的规则包括:
物流成本管理的中心环节是物流成本()。
唐开元年间,高丽人与百济人因琐事在京师地区发生殴斗,两人被政府羁押审制。依唐律,该案应适用的法律是()(2018年一综一第39题)
WhenLauraLangankifoundextratowelsinthelaundrysmellinglemonyfresh,shenever【C1】______thatmeanther13-year-oldson
最新回复
(
0
)